Mousavi S, Nouri S, Sadeghipour A, Atashi A
Ann Hematol. 2025; .
PMID: 39994019
DOI: 10.1007/s00277-025-06237-w.
Kroos S, Blomberg N, Kwekkeboom J, Hendriks R, Corneth O, Toes R
Eur J Immunol. 2025; 55(1):e202451361.
PMID: 39821328
PMC: 11739663.
DOI: 10.1002/eji.202451361.
Zhao D, Huai G, Yuan Y, Cui Y, Yuan Y, Zhao G
Int J Mol Med. 2024; 55(2).
PMID: 39670296
PMC: 11670864.
DOI: 10.3892/ijmm.2024.5470.
Cabrera-Reyes F, Contreras-Palacios T, Ulloa R, Jara-Wilde J, Caballero M, Quiroga C
Life Sci Alliance. 2024; 8(1).
PMID: 39448266
PMC: 11502673.
DOI: 10.26508/lsa.202402917.
Han Z, Benlagha K, Lee P, Park C, Filatov A, Byazrova M
Front Immunol. 2024; 15:1459527.
PMID: 39445011
PMC: 11496051.
DOI: 10.3389/fimmu.2024.1459527.
Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.
Kim C, Park J, Choi Y, Jun H, Chung J, Park T
Front Endocrinol (Lausanne). 2024; 15:1420024.
PMID: 39280007
PMC: 11392736.
DOI: 10.3389/fendo.2024.1420024.
Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy.
Fernandez Turizo M, Kim E, Zhang C, Yankama T, von Keudell G, Sermer D
Oncologist. 2024; 30(2).
PMID: 39244718
PMC: 11886567.
DOI: 10.1093/oncolo/oyae229.
Virus-driven dysregulation of the BCR pathway: a potential mechanism for the high prevalence of HIV related B-cell lymphoma.
Liang Y, Chen X, Zhang X, Guo C, Zhang Y
Ann Hematol. 2024; 103(12):4839-4849.
PMID: 39196379
DOI: 10.1007/s00277-024-05959-7.
Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.
Manzari Tavakoli G, Yazdanpanah N, Rezaei N
Adv Rheumatol. 2024; 64(1):61.
PMID: 39169436
DOI: 10.1186/s42358-024-00401-y.
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.
Song P, Wan Z, Huang G, Song Z, Zhang T, Tong L
Acta Pharmacol Sin. 2024; 45(10):2163-2173.
PMID: 38834683
PMC: 11420226.
DOI: 10.1038/s41401-024-01311-x.
Single-cell transcriptomic atlas of distinct early immune responses induced by SARS-CoV-2 Proto or its variants in rhesus monkey.
Yang Y, Du T, Yu W, Zhou Y, Yang C, Kuang D
MedComm (2020). 2023; 4(6):e432.
PMID: 38020713
PMC: 10661830.
DOI: 10.1002/mco2.432.
A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects.
Zhu L, Shi R, Zhao T, Ye Y, Tang J, Hu Y
Clin Transl Sci. 2023; 16(10):1982-1996.
PMID: 37551782
PMC: 10582678.
DOI: 10.1111/cts.13606.
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Song Y, Zhou K, Yang S, Hu J, Zou D, Gao S
Invest New Drugs. 2023; 41(4):606-616.
PMID: 37420136
PMC: 10447591.
DOI: 10.1007/s10637-023-01376-1.
Inborn errors of human B cell development, differentiation, and function.
Tangye S, Nguyen T, Deenick E, Bryant V, Ma C
J Exp Med. 2023; 220(7).
PMID: 37273190
PMC: 10242086.
DOI: 10.1084/jem.20221105.
B cell activation via immunometabolism in systemic lupus erythematosus.
Iwata S, Hajime Sumikawa M, Tanaka Y
Front Immunol. 2023; 14:1155421.
PMID: 37256149
PMC: 10225689.
DOI: 10.3389/fimmu.2023.1155421.
Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases.
Hu Y, Li Q, Wang P, Li X, Hu Z
Front Oncol. 2023; 13:1140813.
PMID: 37182123
PMC: 10172652.
DOI: 10.3389/fonc.2023.1140813.
The Role of mA Modifications in B-Cell Development and B-Cell-Related Diseases.
Wang S, Li H, Lian Z, Deng S
Int J Mol Sci. 2023; 24(5).
PMID: 36902149
PMC: 10003095.
DOI: 10.3390/ijms24054721.
Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y, Nam S, Moon A
Arch Pharm Res. 2023; 46(3):131-148.
PMID: 36877356
DOI: 10.1007/s12272-023-01433-6.
Immunoglobulin M-degrading enzyme of (Ide ) impairs porcine B cell signaling.
Breitfelder A, Schrodl W, Rungelrath V, Baums C, Alber G, Schutze N
Front Immunol. 2023; 14:1122808.
PMID: 36875121
PMC: 9980343.
DOI: 10.3389/fimmu.2023.1122808.
Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.
Akasaka D, Iguchi S, Kaneko R, Yoshiga Y, Kajiwara D, Nakachi Y
PLoS One. 2023; 18(2):e0282117.
PMID: 36821545
PMC: 9949657.
DOI: 10.1371/journal.pone.0282117.